ClinicalTrials.gg
RecruitingNCT05706558Updated Sep 9, 2026

Retrospective Review of Esophageal Cancer at MSKCC

An observational study in Esophageal Cancer and Esophagus Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Dec 2016; still recruiting 9 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Esophageal Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · Memorial Sloan Kettering Cancer Center.

Started
2016
with 1 other
Observational
8 of 42
2 open now
Registered
38th of 42
by date

Among the 42 studies in Esophageal Neoplasms by Memorial Sloan Kettering Cancer Center, this one is one of 2 that started in 2016, is one of 8 observational ones, and was the 38th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

4 of the 42 studies in Esophageal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Esophageal Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.

03

Conditions studied

  • Esophageal Cancer
  • Esophagus Cancer

Keywords

  • Esophageal Cancer
  • Esophagus Cancer
  • Memorial Sloan Kettering Cancer Center
  • 16-1631
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants undergoing esophagectomy for histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) during the period from 2000 to 2019.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
  • Pathologic staged T3 tumors (pT3)

Exclusion criteria

Exclusion Criteria:

  • Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
  • Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
  • Patients undergoing salvage esophagectomy
  • Evidence of distant disease
  • Patients with a positive proximal or distal margin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Circumferential resection margin (CRM)

    Participants will have a diagnosis of esophageal carcinoma and residual tumor \>1 mm from the CRM

    Procedure: Esophagectomy

  • Circumferential resection margin (CRM)-close

    Participants will have a diagnosis of esophageal carcinoma and residual tumor \>0-1 mm from the CRM

    Procedure: Esophagectomy

  • Circumferential resection margin (CRM)+

    Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM

    Procedure: Esophagectomy

Interventions

  • ProcedureEsophagectomy

    Esophagectomy

06

What researchers measure

Primary outcomes

  1. . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)

    Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall survival and progression-free survival (measured from date of surgery)

    Postoperative outcomes stratified by the type of esophageal cancer surgery performed.

    Time frame: Up to 2 years

  2. Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).

    Time frame: Up to 2 years

  3. Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).

    Time frame: Up to 2 years

  4. Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Daniela Molena, MD · Contact212-639-3870
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2016 (actual). Primary completion is estimated for Feb 2027, 122 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Jan 31, 2023
StartActual
Dec 13, 2016
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05706558
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Dec 13, 2016
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Daniela Molena, MD
Contact
molenad@mskcc.org
212-639-3870
James Isbell, MD
Contact
isbellj@mskcc.org
212-639-6247
Daniela Molena, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion